PTC India reported a standalone net profit of Rs 113.23 crore for Q2 FY27, down from Rs 133.82 crore in the year-ago period, despite higher revenue. The company saw a key relief for its subsidiary, PTC India Financial Services (PFS), which met the RBI’s 75% infrastructure finance threshold. Additionally, PFS received approval to reverse a Rs 191.20 crore impairment reserve, strengthening its balance sheet position.
PTC India Q2 FY27 Results and Subsidiary Regulatory Compliance
Standalone Revenue: Rs 5,701.88 crore | Standalone Net Profit: Rs 113.23 crore
Reader Takeaway: Revenue growth fails to offset profit decline, but subsidiary regulatory compliance and impairment reversals provide positive balance sheet support.
What just happened
PTC India reported its unaudited financial results for the quarter ended September 30, 2026. While standalone revenue grew to Rs 5,701.88 crore from Rs 5,326.89 crore in the same quarter last year, net profit declined to Rs 113.23 crore compared to Rs 133.82 crore in Q2 FY26. Consolidated net profit also saw a reduction, dropping to Rs 159.10 crore from Rs 222.05 crore in the prior year.
Why this matters
The most significant development lies with the subsidiary, PTC India Financial Services (PFS). PFS successfully reached the 75% infrastructure finance exposure threshold required by the Reserve Bank of India (RBI) to retain its status as an NBFC-IFC. This compliance was certified by an independent audit firm on October 23, 2026. Furthermore, the RBI granted approval for PFS to reverse an impairment reserve of Rs 191.20 crore, a move that improves the subsidiary's reported financial standing.
The backstory
PFS had been working under an RBI-granted extension to reach its infrastructure exposure targets. Meeting this goal by the September 30, 2026 deadline effectively resolves a period of regulatory uncertainty for the subsidiary. Simultaneously, the company cleaned up its books by technically writing off equity investments in associate firms RS India Wind Energy Private Limited and Varam Bio Energy Private Limited, which had been previously impaired and now carry no impact on consolidated results.
Risks to watch
Despite the regulatory wins at the subsidiary level, the broader financial results show margin compression, as evidenced by the year-on-year profit decline on both standalone and consolidated bases. Investors should monitor whether the operational revenue growth can translate into improved bottom-line performance in the coming quarters.